gtmagency
gtmagency
×
Previously ran growth for 500+ SaaS companies through their product launches. Our team has also worked with companies backed by
This playbook maps ViewMind's ideal customer profile across account, prospect, and persona dimensions, then lays out 5 signal-based outbound plays. Each play fires on a specific buying signal so your outreach lands the moment a prospect is most likely to act.
| Dimension | Qualified | Prioritization |
|---|---|---|
| Geography | United States, EU (Germany, Spain, UK), Latin America (Brazil, Argentina, Colombia), Southeast Asia | Tier 1: US and EU. Tier 2: LatAm and SEA where ViewMind has existing operations |
| Employee Count | 5 to 500 employees for preventive health clinics and research sites. 500 plus for pharma, biotech, and hospital systems | Tier 1: 20 to 200 for specialty clinics. Tier 1: 200 plus for pharma and CROs |
| Industry / Vertical | Longevity centers, concierge medicine, integrative and functional medicine, executive health programs, neurology clinics, memory centers, academic medical centers, hospital systems, pharma, biotech, CROs | Tier 1: Longevity and concierge medicine (fastest sales cycle). Tier 1: Pharma and CROs (highest ACV). Tier 2: Academic and hospital systems |
| Key Qualifying Signal | Active neurology, memory, or cognitive wellness program with no objective digital biomarker tool in current protocol | Highest priority: accounts advertising cognitive assessment, brain health, or neurological care with no mention of digital biomarker or objective measurement tool |
| Tech Stack | EHR platforms (Epic, Athenahealth, Cerner), telemedicine infrastructure, clinical trial management systems (Medidata, Veeva Vault), REDCap for research sites | Prioritize accounts using clinical trial management systems or research-grade EHRs. Deprioritize pure telehealth-only practices |
| Revenue / Funding | Preventive clinics: revenue generating and self-funded. Pharma and biotech: Series A plus or revenue generating. CROs: established with active neurology trial portfolio | Tier 1: Pharma and biotech with active CNS or Alzheimer pipeline. Tier 1: Longevity clinics with premium membership model. Tier 2: Academic institutions with active NIH or ADDF grants |
| Intent Signals | Hiring for cognitive assessment staff, publishing job posts for neuropsychologists, attending brain health or neurology conferences, downloading cognitive assessment whitepapers, researching digital biomarker vendors on G2 or LinkedIn | Highest priority: active hiring for cognitive or neuropsychology roles plus recent conference attendance. Secondary: content engagement on brain health topics |
| Dimension | Qualified | Prioritization |
|---|---|---|
| Seniority | Director, VP, C-Suite, Principal Investigator, Medical Director | Tier 1: Medical Director, Chief Medical Officer, VP of Clinical Operations. Tier 2: Director of Research, Principal Investigator |
| Primary Titles | Medical Director, Chief Medical Officer, Director of Clinical Operations, Principal Investigator, VP Clinical Development, Head of Neurology, Director of Cognitive Health | Prioritize titles with budget authority and protocol design ownership |
| Secondary Influencers | Neuropsychologist, Clinical Research Coordinator, VP of Scientific Affairs, Head of Digital Health, Clinical Data Manager | Engage as champions and technical validators after primary contact is warmed |
| LinkedIn Keywords | cognitive assessment, brain health, neurodegeneration, MCI, Alzheimer's research, digital biomarker, oculomotor, neuropsychological testing, clinical trial endpoints, precision neurology, longevity medicine, executive health | Highest signal: profiles using digital biomarker or objective cognitive measurement language. Secondary: longevity medicine and precision health language |
| Persona | Level | KPIs | Related Challenges | Intent Signals | Related Benefits |
|---|---|---|---|---|---|
| Medical Director, Longevity or Concierge Clinic | Director / C-Suite | Patient retention rate, premium membership renewal, differentiated service offerings, patient outcomes scores | Lack of objective tools to justify cognitive wellness protocols, reliance on subjective or paper-based assessments, difficulty demonstrating measurable cognitive change to patients | Hiring neuropsychology staff, posting about brain health content on LinkedIn, attending longevity or executive health conferences | 10-minute non-invasive baseline assessment that produces objective, reproducible data to anchor wellness programs and demonstrate measurable patient outcomes |
| VP Clinical Development, Pharma or Biotech | VP / C-Suite | Trial enrollment velocity, endpoint sensitivity, regulatory submission readiness, biomarker validation milestones | Insensitive endpoints that miss early functional change, high screen failure rates in MCI and Alzheimer's trials, need for remote or decentralized assessment options | Active CNS or Alzheimer's pipeline, job posts for clinical biomarker roles, presenting at neurology congresses, researching digital endpoints | Physiological eye-tracking endpoints sensitive to early functional change, validated against 20 plus standard neuropsychological assessments, reproducible enough for longitudinal study designs |
| Principal Investigator, Academic Medical Center or CRO | Director / VP | Publication output, grant renewal, protocol compliance, data quality scores, site performance metrics | Dependence on rater-administered cognitive tests with high variability, difficulty scaling assessments across sites, lack of continuous physiological data | Active NIH or ADDF grants, posting about cognitive research methodology, attending CTAD or AAIC conferences | Objective, continuous oculomotor data that reduces rater variability, scales across sites, and supports longitudinal study designs with high reproducibility |
| Chief Medical Officer, Hospital System or Memory Center | C-Suite | Patient throughput, diagnostic accuracy, length of care pathway, payer reimbursement capture, population health outcomes | No scalable objective tool for early cognitive decline detection, overreliance on neurologist time for screening, difficulty tracking patients longitudinally | Expanding memory care programs, posting about dementia or cognitive screening initiatives, partnering with academic centers on brain health | Scalable 10-minute assessment administered by non-specialist staff, delivers objective clinical report to support diagnostic decision-making and longitudinal monitoring |
| Head of Digital Health or Innovation, Health System or Pharma | Director / VP | Technology adoption rate, clinical workflow integration, ROI on digital health investments, regulatory pathway progress | Evaluating digital biomarker vendors with limited clinical validation evidence, concern about FDA clearance status and compliance, integration with existing EHR and trial systems | Attending digital health or health innovation events, evaluating vendors on G2 or similar platforms, posting about digital biomarkers or AI in clinical trials | 25 patents, 80 plus peer-reviewed publications, Harvard and Mayo Clinic partnerships, active FDA clearance pathway, integration-ready platform with established clinical validation |
We identify companies actively building out cognitive assessment infrastructure for clinical trials and reach out to VP Clinical Development and Principal Investigator contacts before vendor decisions are made. This play targets the earliest point in the buying cycle when the need is confirmed but the solution is not yet chosen.
Job Post Monitor
LinkedIn Jobs Scrape
Company Signal Feed
Firmographic Enrich
Contact Waterfall
Email VerificationIdentify Buying Committee
Email
LinkedInWe target longevity and concierge clinic Medical Directors and CMOs at the moment they are building or expanding service protocols, positioning ViewMind Neuroscan as the objective brain health anchor for their cognitive wellness offering. New location and new hire signals confirm budget availability and protocol design activity.
Job Post MonitorLinkedIn Company Posts
Web Signal ScrapeClinic Profile EnrichDecision Maker LookupEmail VerificationEmail
LinkedInWe scrape or source conference attendee and speaker data from Alzheimer's and neurology congresses and reach out immediately post-event to Principal Investigators, VP Clinical Development, and Medical Directors while the topic is top of mind. ViewMind's existing Alzheimer's and MCI study partnerships make this outreach highly relevant.
Conference Attendee ScrapeLinkedIn Event ScrapeSpeaker List EnrichContact and Firm EnrichEmail WaterfallPipeline and Trial LookupIdentify Buying CommitteeEmailLinkedInWe track job changes of known ViewMind contacts and engaged prospects using UserGems, then trigger outreach within the first 30 days of their new role when they have the most influence over new vendor and protocol decisions. Warm prior relationship accelerates the sales cycle significantly.
Champion Job Change AlertLinkedIn Profile MonitorNew Account EnrichNew Contact VerifyAccount Fit ScoreIdentify Buying CommitteeEmailLinkedInWe de-anonymize high-intent website visitors from target account domains who browse ViewMind's product and solution pages, identify the buying committee at those accounts, and launch same-day personalized outreach to the most relevant decision maker before the prospect evaluates a competitor.
Website Visitor Capture
Account Intent Layer
Bombora Intent FeedVisitor Identity EnrichBuying Committee LookupEmail VerificationBuying CommitteeEmailYou'll have qualified demos booked in your calendar within 45 days: infrastructure, sequences, and live campaigns installed for you.
You don't pay a retainer. Everything we build belongs to you from day one: data, playbooks, and infrastructure.
If by day 45 you aren't seeing qualified demos booked in your calendar, we keep working completely for free until you do.
We build and install a fully automated, signal-based outbound system, outbound, ads, and content, in a 45-day sprint. No retainer, and you own everything. Demos booked in 45 days or we work free until they are.
